The Madras High Court's examination of Section 107A in the Novartis AG case provides greater clarity on the evidentiary standards for the Bolar exemption, raising concerns about the burdens on manufacturers that could undermine the exemption's intent.
Clarity on Bolar Exemption in Novartis AG Case
The Madras High Court has issued a landmark ruling in Novartis AG v. Venkata Narayana Active Ingredients, scrutinizing the evidentiary requirements necessary to invoke Section 107A concerning the Bolar exemption. This judicial review marks a significant progression in understanding how evidence is evaluated within this context, particularly for manufacturers seeking regulatory approvals for generic drugs.
The Court's efforts to clarify the evidentiary standards applicable to the Bolar exemption are commendable. However, practitioners have raised concerns that the new standards may impose undue burdens on pharmaceutical manufacturers, potentially counteracting the exemption's intended purpose of facilitating market entry for generics.
This ruling carries significant implications for patent law practitioners and manufacturers alike. It emphasizes the importance of aligning evidentiary practices with the original legislative intent, which could lead to a reexamination of current strategies deployed by generic manufacturers as they navigate regulatory frameworks.
Citations
- Novartis AG v. Venkata Narayana Active Ingredients (2026) 6 Mad 205
